Efficacy and safety of continuous every 2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase 3 trial (IXORA-P).
| Image |  |
|---|---|
| Description | scientific article published on 6 February 2018 |
| Author/s |
author: Kim A. Papp Andrew Blauvelt |
| Publication date | May 15, 2018 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |